New Strategies in Colorectal Cancer: Biomarkers of Response to Epidermal Growth Factor Receptor Monoclonal Antibodies and Potential Therapeutic Targets in Phosphoinositide 3-Kinase and Mitogen-Activated Protein Kinase Pathways

被引：35

作者：

Dasari, Arvind ^{[1
]}

Messersmith, Wells A. ^{[1
]}

机构：

[1] Univ Colorado, Ctr Canc, Gastrointestinal Med Oncol Program, Aurora, CO 80045 USA

来源：

CLINICAL CANCER RESEARCH | 2010年 / 16卷 / 15期

关键词：

BRAF V600E MUTATION; K-RAS MUTATIONS; TUMOR PROGRESSION; PIK3CA MUTATIONS; KRAS MUTATIONS; GENE-MUTATIONS; COLON-CANCER; CETUXIMAB; EXPRESSION; STAGE;

D O I：

10.1158/1078-0432.CCR-09-2283

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Initial experience with the epidermal growth factor receptor monoclonal antibodies (EGFR MoAb) in unselected patients with metastatic colorectal cancer (mCRC) showed that most of the treated patients did not derive therapeutic benefit. This outcome has driven the search for biomarkers for this population. Recent advances have further shown the heterogeneous nature of this disease with multiple interlinked pathways being implicated. Two such pathways downstream to the EGFR, mitogen-activated protein kinase (MAPK) and (phosphoinositide 3-kinase) PI3K, have gained increasing attention and become targets for development of novel biomarkers and therapeutic agents. Here, we highlight recent progress. Clin Cancer Res; 16(15); 3811-8. (C) 2010 AACR.

引用

页码：3811 / 3818

页数：8

共 68 条

[1] American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy [J].

Allegra, Carmen J. ;

Jessup, J. Milburn ;

Somerfield, Mark R. ;

Hamilton, Stanley R. ;

Hammond, Elizabeth H. ;

Hayes, Daniel F. ;

McAllister, Pamela K. ;

Morton, Roscoe F. ;

Schilsky, Richard L. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (12) :2091-2096

[2] Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer [J].

Banck, Michaela S. ;

Grothey, Axel .

CLINICAL CANCER RESEARCH, 2009, 15 (24) :7492-7501

[3]

BENDELL J, 2010, P ASCO GASTR CANC S

[4] Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan [J].

Bibeau, Frederic ;

Lopez-Crapez, Evelyne ;

Di Fiore, Frederic ;

Thezenas, Simon ;

Ychou, Marc ;

Blanchard, France ;

Lamy, Aude ;

Penault-Llorca, Frederique ;

Frebourg, Thierry ;

Michel, Pierre ;

Sabourin, Jean-Christophe ;

Boissiere-Michot, Florence .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (07) :1122-1129

[5] Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer [J].

Bokemeyer, Carsten ;

Bondarenko, Igor ;

Makhson, Anatoly ;

Hartmann, Joerg T. ;

Aparicio, Jorge ;

de Braud, Filippo ;

Donea, Serban ;

Ludwig, Heinz ;

Schuch, Gunter ;

Stroh, Christopher ;

Loos, Anja H. ;

Zubel, Angela ;

Koralewski, Piotr .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :663-671

[6] K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study [J].

Brink, M ;

de Goeij, AFPM ;

Weijenberg, MP ;

Roemen, GMJM ;

Lentjes, MHFM ;

Pachen, MMM ;

Smits, KM ;

de Bruïne, AP ;

Goldbohm, RA ;

van den Brandt, PA .

CARCINOGENESIS, 2003, 24 (04) :703-710

[7]

CATLING AD, 1995, MOL CELL BIOL, V15, P5214

[8] Drug therapy: EGFR antagonists in cancer treatment [J].

Ciardiello, Fortunato ;

Tortora, Giampaolo .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (11) :1160-1174

[9] Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[10] MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events [J].

de Vogel, S. ;

Weijenberg, M. P. ;

Herman, J. G. ;

Wouters, K. A. D. ;

de Goeij, A. F. P. M. ;

van den Brandt, P. A. ;

de Bruine, A. P. ;

van Engeland, M. .

ANNALS OF ONCOLOGY, 2009, 20 (07) :1216-1222

← 1 2 3 4 5 6 7 →